WHAT THE CURRENT EVIDENCE SAYS
For years, hormone replacement therapy, now often called menopausal hormone therapy, has been one of the most debated treatments in women’s health. Some women were told it was dangerous. Others were told it was almost a fountain of youth. The truth is more balanced. Current evidence supports hormone therapy for the right woman, at the right time, for the right reason.
Hormone therapy replaces some of the estrogen that drops after menopause. If a woman still has her uterus, she usually also needs progesterone or a progestin to protect the lining of the uterus from cancer. If she has had a hysterectomy, estrogen alone may be used. Hormone therapy can be taken as a pill, patch, gel, spray, vaginal ring, cream, or tablet. The form matters because pills, patches, and vaginal treatments do not all carry the same risks.
The strongest evidence for hormone therapy is for relief of hot flashes and night sweats. These symptoms can be more than annoying. They can disrupt sleep, mood, work, relationships, and quality of life. The Menopause Society states that hormone therapy is FDA-approved as a first-line treatment for bothersome hot flashes and is the most effective treatment available. Benefits are most favorable for healthy women who start treatment before age 60 or within 10 years of menopause.
Hormone therapy also helps vaginal and urinary symptoms of menopause. Low estrogen can cause vaginal dryness, pain with sex, burning, recurrent urinary symptoms, and irritation. For women whose main problem is vaginal dryness or pain, low-dose vaginal estrogen is often enough. Because it has very low absorption into the bloodstream, it is generally considered lower risk than whole-body hormone therapy.
Another clear benefit is bone protection. Estrogen slows bone loss after menopause and can reduce fracture risk. This can matter for women at high risk for osteoporosis, especially if they also have menopausal symptoms. However, hormone therapy is usually not started only to prevent chronic disease in women without symptoms. The U.S. Preventive Services Task Force recommends against using estrogen-progestin or estrogen-alone therapy solely to prevent chronic diseases in postmenopausal women.
The biggest shift in thinking has been about timing. Older studies, especially the Women’s Health Initiative, raised concerns about breast cancer, heart disease, stroke, blood clots, and dementia. Those findings were important, but many women in those trials were older and many years past menopause. Later analyses suggest risks are lower, and benefits often outweigh risks, when hormone therapy is started in healthy women closer to menopause. Starting therapy after age 60, after age 70, or more than 10 years after menopause is a different discussion and may carry higher risk.
Heart health is one area where the message must be careful. Hormone therapy should not be sold as a heart disease prevention drug. The WHI randomized trials do not support using menopausal hormone therapy to prevent cardiovascular disease or other chronic illnesses. Still, for a healthy woman near menopause who needs symptom relief, heart risk may be low, especially when using lower doses or non-oral options such as patches.
Breast cancer risk depends on the type of therapy, length of use, and the woman’s personal risk. Estrogen plus progestin appears to carry more breast cancer concern than estrogen alone. Women with a personal history of breast cancer usually need special guidance and often avoid systemic hormone therapy. Women with a uterus should not take estrogen alone because it can increase the risk of uterine cancer unless the uterus has been removed.
Blood clots and stroke are also important. Oral estrogen can increase clot risk more than transdermal estrogen, such as patches or gels. This is why the route of treatment matters. A woman with a history of blood clots, stroke, heart attack, certain cancers, unexplained vaginal bleeding, or active liver disease may not be a good candidate for systemic hormone therapy.
What about brain health? This is still uncertain. Hormone therapy should not be used mainly to prevent dementia. Some observational studies have raised concern, while newer reviews suggest the dementia effect may be neutral. The safest conclusion is that hormone therapy is useful for menopause symptoms, not as a proven brain-protection treatment.
In 2025, the FDA moved to remove long-standing boxed warnings from several hormone-based menopause treatments. This reflects a growing view that the old warning was too broad and did not clearly separate younger symptomatic women from older women starting therapy later. Still, experts continue to stress individualized decision-making rather than a one-size-fits-all approach.
The bottom line is this: hormone therapy is not for every woman, but it should not be feared by every woman either. For healthy women under 60 or within 10 years of menopause who have moderate to severe hot flashes, night sweats, sleep disruption, or vaginal symptoms, the evidence supports a thoughtful discussion. The goal is to use the right dose, the right route, and the right duration, with regular follow-up.
Menopause is not a disease. But for some women, the symptoms can be life-changing. For those women, hormone therapy may be one of the most effective tools we have.